liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
St Olavs Hospital, Norway; Norwegian University of Science and Technology NTNU, Norway.
Aarhus University Hospital, Denmark.
Skåne University Hospital, Sweden.
University of Helsinki, Finland; Helsinki University Hospital, Sweden.
Show others and affiliations
2016 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 30, no 9, 1853-1860 p.Article in journal (Refereed) Published
Abstract [en]

Dasatinib (DAS) and interferon-a have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-alpha 2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 mu g/week and it increased to 25 mu g/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR4 was achieved by 46% and MR4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS +/- PegIFN is warranted.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP , 2016. Vol. 30, no 9, 1853-1860 p.
National Category
Hematology
Identifiers
URN: urn:nbn:se:liu:diva-132071DOI: 10.1038/leu.2016.121ISI: 000383786400003PubMedID: 27133821OAI: oai:DiVA.org:liu-132071DiVA: diva2:1038424
Note

Funding Agencies|Bristol-Myers Squibb; Norwegian University of Science and Technology (NTNU, Trondheim, Norway)

Available from: 2016-10-18 Created: 2016-10-17 Last updated: 2016-10-18

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Dreimane, Arta
By organisation
Department of Clinical and Experimental MedicineFaculty of Health SciencesDepartment of Haematology
In the same journal
Leukemia
Hematology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 6 hits
ReferencesLink to record
Permanent link

Direct link